Xenon Pharmaceuticals Inc.
XENE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $3 | $2 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $3 | $2 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -48.8% | – |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -1,354% | -423.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -1,328.9% | -427.8% |
| EPS Diluted | -3.01 | -2.73 | -2.06 | -1.77 |
| % Growth | -10.3% | -32.5% | -16.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |